EODData

MEMBERSHIP REGISTER LOG IN

FRA, 30O: ONCOTHERAPY SCIENCE INC.

13 Nov 2025
LAST:

0.1090

CHANGE:
 0.00		OPEN:
0.1090		HIGH:
0.1090		ASK:
0.0000		VOLUME:
64
CHG(%):
0.00		PREV:
0.1090		LOW:
0.1090		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Nov 250.10900.10900.10900.109064
12 Nov 250.10900.10900.10900.109064
11 Nov 250.11000.11000.11000.110064
07 Nov 250.11100.11100.11100.111064
06 Nov 250.11000.11000.11000.110064
05 Nov 250.10500.10500.10500.105064
04 Nov 250.11100.11100.11100.111064
31 Oct 250.11000.11000.11000.110064
30 Oct 250.10400.10400.10400.104064
29 Oct 250.10500.10500.10500.105064

COMPANY PROFILE

Name:ONCOTHERAPY SCIENCE INC.
About:OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company's pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Sector:Healthcare
Industry:Biotechnology
Address:1-2 Higashida-cho, Kawasaki, Japan, 210-0005
Website:https://www.oncotherapy.co.jp
ISIN:JP3202150003
LEI:529900CIAZCAIG781H52

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.04 
Price to Sales:0.04 
Price to Book:0.03 
Profit Margin:-0.97 
Operating Margin:-1.51 
Return on Assets:-0.36 
Return on Equity:-0.92 
Revenue:4.79M 
Shares:277.64M 
Market Cap:30.26M 

TECHNICAL INDICATORS

MA5:0.110.7%
MA10:0.110.6%
MA20:0.110.2%
MA50:0.1212.8%
MA100:0.1321.1%
MA200:0.1320.9%
STO9:71.43
STO14:41.67
RSI14:47.37
WPR14:-58.33
MTM14:0.00
ROC14:-0.02 
ATR:0.00 
Week High:0.111.8%
Week Low:0.110.0%
Month High:0.126.4%
Month Low:0.1020.9%
Year High:0.2191.7%
Year Low:0.0919.8%